Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07839403

MOVE-HIP: Ceramic Hip Resurfacing Versus Total Hip Arthroplasty Using Activity Monitoring

MOVE-HIP is a pragmatic, multicenter randomized clinical trial comparing ceramic hip resurfacing arthroplasty with contemporary total hip arthroplasty in adults with symptomatic hip osteoarthritis who are considered clinically eligible for both procedures. Participants in the randomized cohort are allocated 1:1 to either ceramic hip resurfacing or total hip arthroplasty and are kept blinded to treatment allocation where feasible through the 24-month primary follow-up.

The primary objective is to determine whether ceramic hip resurfacing results in greater objectively measured mean daily walking distance over the postoperative period from 3 to 24 months. Activity is assessed during standardized 7-day wearable monitoring periods at 3, 12, and 24 months. The primary estimand is the adjusted overall between-group difference across these postoperative time points. A parallel observational preference cohort may include otherwise eligible patients who decline randomization; this cohort is analyzed separately and does not contribute to the primary randomized inference.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hip Osteoarthritis Arthritis Behavior Joint Diseases Motor Activity Musculoskeletal Diseases Osteoarthritis Osteoarthritis, Hip Rheumatic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Danderyd Hospital

Danderyd, 182 88, Sweden

Location status: Recruiting

About this study

The trial is designed to test whether a contemporary ceramic-on-ceramic hip resurfacing strategy provides a clinically meaningful advantage over modern total hip arthroplasty in real-world physical activity. Randomization is stratified by study site and sex. All participants undergo baseline assessment including patient-reported outcomes, radiographs, clinical data, and 7-day wearable activity monitoring before surgery.

The randomized cohort includes 220 participants, 110 per treatment group. Follow-up is planned at 3 months, 12 months, 24 months, 5 years, and 10 years. Secondary outcomes include walking distance at 24 months, daily step count, patient-reported outcomes, radiographic outcomes, perioperative outcomes, complications, reoperations, revisions, implant survival, and health-economic outcomes. The study is academically led, and the observational preference cohort follows the same assessment schedule but is analyzed separately.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 years or older.
  • Symptomatic hip osteoarthritis for which primary hip arthroplasty is indicated according to routine clinical practice.
  • Considered suitable for both ceramic hip resurfacing arthroplasty and uncemented total hip arthroplasty by the treating surgeon.
  • Ability and willingness to comply with study procedures, including patient-reported outcome measures, radiographs, registry linkage, and repeated wearable monitoring.
  • Provision of written informed consent.

Exclusion criteria

  • Anatomical or pathological conditions that clearly preclude hip resurfacing arthroplasty or total hip arthroplasty, including severe deformity requiring non-standard implants or techniques.
  • Insufficient femoral head or acetabular bone quality, including large or multiple cysts, advanced femoral head necrosis, severe osteopenia, or osteoporosis where this would contraindicate hip resurfacing arthroplasty.
  • Body mass index greater than 40 kg/m^2.
  • Requirement for specialized implants outside routine study procedures.
  • Medical comorbidity rendering the patient unfit for surgery.
  • Cognitive impairment, severe psychiatric disease, alcohol or substance abuse, language barrier, or other reason judged to prevent informed consent or compliance with follow-up.
  • Inability to complete patient-reported outcome measures or to participate in wearable monitoring.

Treatment and study plan

Ceramic-on-Ceramic Hip Resurfacing Arthroplasty

Procedure

Cementless ceramic-on-ceramic hip resurfacing arthroplasty. The currently planned study implant is H1, or a subsequent equivalent generation if applicable. Procedures are performed by surgeons with documented arthroplasty experience and system-specific training.

Other names: H1 ceramic hip resurfacing

Contemporary Total Hip Arthroplasty

Procedure

Contemporary standard primary total hip arthroplasty using established implants and bearing combinations according to local routine and individual clinical assessment. Implant choice remains clinically appropriate for the individual participant.

Primary outcomes

  1. Mean Daily Walking Distance Over the Postoperative Period From 3 to 24 Months

    Time frame: 3, 12, and 24 months after surgery

    Mean daily walking distance is assessed during standardized 7-day wearable monitoring periods at each postoperative time point. The primary estimand is the adjusted overall between-group difference in mean daily walking distance across 3, 12, and 24 months, with adjustment for preoperative walking distance and prespecified covariates.

Secondary outcomes

  1. Mean Daily Walking Distance at 24 Months

    Time frame: 24 months after surgery

    Mean daily walking distance derived from a standardized 7-day wearable monitoring period at 24 months.

  2. Mean Daily Step Count Over the Postoperative Period From 3 to 24 Months

    Time frame: 3, 12, and 24 months after surgery

    Mean daily step count derived from standardized 7-day wearable monitoring periods at 3, 12, and 24 months.

  3. Forgotten Joint Score-12 (FJS-12) at 24 Months

    Time frame: 24 months after surgery

    Joint awareness assessed using the Forgotten Joint Score-12 (FJS-12). Scores range from 0 to 100, with higher scores indicating less awareness of the operated joint during everyday activities and a better outcome.

  4. Proportion of Participants With FJS-12 Score of 80 or Higher

    Time frame: 24 months after surgery

    Proportion of participants achieving a Forgotten Joint Score-12 (FJS-12) of at least 80. The scale ranges from 0 to 100, with higher scores indicating less awareness of the operated joint during everyday activities and a better outcome.

  5. Hip Disability and Osteoarthritis Outcome Score (HOOS) Subscales

    Time frame: 24 months after surgery

    HOOS Pain, Symptoms, Activities of Daily Living, Sport/Recreation, and Quality of Life subscales at 24 months. Each subscale ranges from 0 to 100, with higher scores indicating better status.

  6. University of California, Los Angeles (UCLA) Activity Score

    Time frame: 24 months after surgery

    Self-reported habitual physical activity level assessed using the University of California, Los Angeles (UCLA) Activity Score. Scores range from 1 to 10, with higher scores indicating a higher level of physical activity and a better activity-related outcome.

  7. High-Activity Arthroplasty Score (HAAS)

    Time frame: 24 months after surgery

    Self-reported functional ability assessed using the High-Activity Arthroplasty Score (HAAS), covering walking, running, stair climbing, and activity level. Total scores range from 0 to 18, with higher scores indicating greater functional ability and a better outcome.

  8. EuroQol 5-Dimension (EQ-5D-5L Index)

    Time frame: 24 months after surgery

    Health-related quality of life assessed using the EQ-5D-5L questionnaire. Responses are converted into an index using the Swedish experience-based time trade-off value set (Burström et al., 2020). Index values range from approximately 0.243 to 0.975, with higher values indicating better health-related quality of life.

  9. EuroQol Visual Analogue Scale (EQ VAS)

    Time frame: 24 months after surgery

    Self-rated overall health assessed using the EuroQol Visual Analogue Scale (EQ VAS). Scores range from 0 (the worst health imaginable) to 100 (the best health imaginable), with higher scores indicating better perceived health.

  10. Radiographic Implant and Hip Biomechanics Outcomes

    Time frame: 24 months after surgery

    Radiographic assessment includes component orientation and fixation, radiolucent lines, migration or loosening, heterotopic ossification, leg length and offset where feasible. In the hip resurfacing group, femoral neck integrity, notching, narrowing, fracture, femoral head movement or crushing, and component alignment are additionally assessed.

  11. Adverse Events and Postoperative Complications

    Time frame: From surgery through 24 months

    Incidence and type of adverse events and complications, including infection, dislocation, periprosthetic fracture, femoral neck fracture, implant fracture, thromboembolic events, nerve injury, wound complications, persistent pain, and other procedure- or implant-related events.

  12. Reoperations and Revisions of the Index Hip

    Time frame: From surgery through 24 months

    Number and proportion of participants undergoing reoperation or revision of the index hip, including reason and components exchanged or removed.

  13. Health-Economic Outcomes

    Time frame: From surgery through 24 months

    Quality-adjusted life years derived from EQ-5D and incremental cost-effectiveness comparing ceramic hip resurfacing with total hip arthroplasty over 24 months, using available direct and indirect cost data.

  14. Long-Term Implant Survival

    Time frame: 5 and 10 years after surgery

    Revision-free implant survival assessed using study follow-up and registry data at 5 and 10 years.

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

Danderyd Hospital

Other

Collaborators

  • Hässleholm Hospital
  • Karolinska Institutet
  • Ortopediskt Centrum

Registry information

Official study title

A Pragmatic, Multicenter, Patient-Blinded, Preference-Tolerant Randomized Clinical Trial Comparing Ceramic Hip Resurfacing With Total Hip Arthroplasty Using Activity Monitoring

Acronym: MOVE-HIP

Important dates

Study start
2026
Primary completion
2031
Study completion
2039
First posted
Sep 24, 2026
Registry last updated
Sep 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.